Ambrus Julian L, Dembinski Wlodzimierz, Ambrus Julian L, Sykes Donald E, Akhter Selina, Kulaylat Mahmoud N, Islam Abul, Chadha Kailash C
Department of Internal Medicine and Surgery, State University of New York at Buffalo School of Medicine and Medical Sciences-Buffalo General Hospital/Kaleida Health System, Buffalo, New York 14203, USA.
Cancer. 2003 Dec 15;98(12):2730-3. doi: 10.1002/cncr.11843.
Many viral and neoplastic diseases are resistant to interferon-alpha/beta (IFN-alpha/beta) therapy or develop resistance during the course of IFN treatment. In patients with viral diseases, the authors identified four IFN inhibitors, of which the most important, most likely is a free IFN receptor of type 1 appearing in the circulation that captures and neutralizes IFN-alpha/beta.
Ninety-one cancer patients and 25 healthy individuals were studied. Free circulating IFN receptor-alpha/beta type 1 was studied. The patients were ages 35-75 years. The diagnoses were 24 cases of colon carcinoma, 7 cases of prostate carcinoma, 16 cases of breast carcinoma, 8 cases of ovarian carcinoma, 9 cases of uterine carcinoma, 5 cases of lung carcinoma, 3 cases of astrocytoma, 4 cases of transitional cell carcinoma of the bladder, 1 case of osteosarcoma, 3 cases of multiple myeloma, 4 cases of Hodgkin disease, 2 cases of non-Hodgkin lymphoma, 3 cases of myelodysplastic syndrome, and 2 disseminated tumors of unknown origin.
All patients were found to have increased free IFN receptor-alpha/beta type 1 in the circulation, with the highest levels reported in patients with adenocarcinoma.
High IFN inhibitory activity in patients with cancer may be a significant factor in their increased susceptibility to progressive disease, infectious complications, and resistance to IFN therapy. Ongoing studies are being performed with the objective of overcoming this inhibitory activity.
许多病毒性和肿瘤性疾病对α/β干扰素（IFN-α/β）治疗耐药，或在IFN治疗过程中产生耐药性。在患有病毒性疾病的患者中，作者鉴定出四种IFN抑制剂，其中最重要、最有可能的是循环中出现的1型游离IFN受体，它能捕获并中和IFN-α/β。
对91例癌症患者和25名健康个体进行了研究。研究了循环中的游离1型IFN受体-α/β。患者年龄在35至75岁之间。诊断包括24例结肠癌、7例前列腺癌、16例乳腺癌、8例卵巢癌、9例子宫癌、5例肺癌、3例星形细胞瘤、4例膀胱移行细胞癌、1例骨肉瘤、3例多发性骨髓瘤、4例霍奇金病、2例非霍奇金淋巴瘤、3例骨髓增生异常综合征以及2例来源不明的播散性肿瘤。
所有患者循环中的游离1型IFN受体-α/β均升高，腺癌患者的水平最高。
癌症患者中较高的IFN抑制活性可能是其对疾病进展、感染并发症易感性增加以及对IFN治疗耐药的一个重要因素。目前正在进行研究以克服这种抑制活性。
